See more : L.P.N. Development Public Company Limited (LPN.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Transphorm, Inc. (TGAN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Transphorm, Inc., a leading company in the Semiconductors industry within the Technology sector.
- Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) Income Statement Analysis – Financial Results
- Swift Networks Group Limited (SW1.AX) Income Statement Analysis – Financial Results
- Huakang Biomedical Holdings Company Limited (8622.HK) Income Statement Analysis – Financial Results
- Enbridge Inc. (EBGEF) Income Statement Analysis – Financial Results
- Suyog Telematics Limited (SUYOG.BO) Income Statement Analysis – Financial Results
Transphorm, Inc. (TGAN)
About Transphorm, Inc.
Transphorm, Inc., a semiconductor company, develops, manufactures, and sells gallium nitride (GaN) semiconductor components for use in power conversion in Mainland China, Hong Kong, Taiwan, the United States, Japan, South Korea, and Europe. The company's products include GaN field effect transistors in various packages. Its GaN devices allows customers to design power systems creating functional value in various end products, including smartphone power adapters/fast-chargers, power supplies for datacenter servers/communication, industrial power converters, chargers/converters/inverters for electric vehicles, and other applications. The company offers its products through regional distributors and sales representatives. Transphorm, Inc. was founded in 2007 and is headquartered in Goleta, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 16.51M | 24.05M | 11.37M | 11.93M | 0.00 |
Cost of Revenue | 17.46M | 12.53M | 6.68M | 6.49M | 0.00 |
Gross Profit | -950.00K | 11.52M | 4.69M | 5.44M | 0.00 |
Gross Profit Ratio | -5.75% | 47.90% | 41.24% | 45.60% | 0.00% |
Research & Development | 8.91M | 6.66M | 5.58M | 8.15M | 0.00 |
General & Administrative | 13.67M | 11.23M | 10.33M | 6.61M | 0.00 |
Selling & Marketing | 5.25M | 3.54M | 2.17M | 2.61M | 0.00 |
SG&A | 18.92M | 14.76M | 12.50M | 9.22M | 0.00 |
Other Expenses | 1.63M | 3.82M | 3.08M | 1.10M | -44.43K |
Operating Expenses | 27.83M | 21.42M | 18.09M | 17.36M | -44.43K |
Cost & Expenses | 45.29M | 33.95M | 24.77M | 23.85M | -44.43K |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 730.00K | 792.00K | 760.00K | 758.00K | 0.00 |
Depreciation & Amortization | 443.00K | 1.30M | -2.92M | -1.39M | 171.86K |
EBITDA | -28.33M | -8.60M | -16.31M | -13.31M | -44.43K |
EBITDA Ratio | -171.61% | -35.76% | -143.47% | -111.52% | 0.00% |
Operating Income | -28.78M | -9.90M | -13.40M | -11.92M | -44.43K |
Operating Income Ratio | -174.29% | -41.15% | -117.82% | -99.87% | 0.00% |
Total Other Income/Expenses | -1.82M | -339.00K | -4.51M | -3.36M | 0.00 |
Income Before Tax | -30.60M | -10.24M | -17.91M | -15.28M | -44.43K |
Income Before Tax Ratio | -185.32% | -42.56% | -157.50% | -128.06% | 0.00% |
Income Tax Expense | 1.09M | 339.00K | 4.51M | 3.36M | 0.00 |
Net Income | -31.69M | -10.57M | -22.42M | -18.65M | -44.43K |
Net Income Ratio | -191.93% | -43.97% | -197.18% | -156.25% | 0.00% |
EPS | -0.56 | -0.23 | -0.71 | -0.53 | 0.00 |
EPS Diluted | -0.56 | -0.23 | -0.71 | -0.53 | 0.00 |
Weighted Avg Shares Out | 56.23M | 46.06M | 31.74M | 35.14M | 0.00 |
Weighted Avg Shares Out (Dil) | 56.23M | 46.06M | 31.74M | 35.14M | 0.00 |
Renesas Completes Acquisition of Transphorm
Transphorm Demonstrates a Bidirectional SuperGaN Power Supply with New Reference Design for E-Mobility and Energy/Industrial Markets
St. Charles County Dermatologic Surgery Joins Epiphany Dermatology
トランスフォーム、PCIM 2024にて「SuperGaN」を披露: 高出力システムにおいて、SiCとeモードGaNの機能を凌駕
Transphorm's SuperGaN at PCIM 2024: Surpassing SiC and e-mode GaN Capabilities in High Power Systems
Transphorm and Weltrend Semiconductor Release New Integrated GaN System-in-Packages
Transphorm and Weltrend Semiconductor Release New Integrated GaN System-in-Packages
URGENT: The M&A Class Action Firm Encourages Shareholders of Transphorm, Inc. to Take Action Before the Merger Vote on April 9, 2024 - TGAN
TRANSPHORM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Transphorm, Inc. - TGAN
Transphorm Announces Fiscal 2024 Third Quarter Results and Provides Business Update
Source: https://incomestatements.info
Category: Stock Reports